CsA
Sponsors
National Heart, Lung, and Blood Institute (NHLBI), European Society for Blood and Marrow Transplantation, Novartis Pharmaceuticals, Chinese PLA General Hospital, Jinan Military General Hospital
Conditions
Aplastic AnemiaHematopoietic Stem Cell TransplantationSevere Aplastic AnemiaaGVHD
Phase 2
Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
CompletedNCT00065260
Start: 2003-11-06End: 2016-02-05Updated: 2021-07-21
Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects
CompletedNCT02404025
Start: 2015-05-12End: 2017-09-06Updated: 2019-07-26
A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia
CompletedNCT03025698
Start: 2017-09-30End: 2025-01-27Updated: 2025-03-04
Phase 3
Phase 4
Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT
CompletedNCT02677181
Start: 2016-01-31End: 2022-04-30Updated: 2022-05-24
ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia
NCT02838992
Start: 2017-02-28End: 2019-07-31Target: 130Updated: 2017-02-01
ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis
NCT04203108
Start: 2019-09-01End: 2022-12-31Target: 266Updated: 2019-12-18